BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34072735)

  • 1. Detection of
    Borkowska EM; Barańska M; Kowalczyk M; Pietruszewska W
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34072735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
    Suda T; Hama T; Kondo S; Yuza Y; Yoshikawa M; Urashima M; Kato T; Moriyama H
    BMC Cancer; 2012 Sep; 12():416. PubMed ID: 22994622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
    Al-Amri AM; Vatte C; Cyrus C; Chathoth S; Hashim TM; Mohamed YS; Al Ali R; Alsaid A; Al Ali A
    Cancer Biomark; 2016; 16(3):377-83. PubMed ID: 26889984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
    García-Escudero R; Segrelles C; Dueñas M; Pombo M; Ballestín C; Alonso-Riaño M; Nenclares P; Álvarez-Rodríguez R; Sánchez-Aniceto G; Ruíz-Alonso A; López-Cedrún JL; Paramio JM; Lorz C
    Oral Oncol; 2018 Apr; 79():55-63. PubMed ID: 29598951
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    García-Carracedo D; Cai Y; Qiu W; Saeki K; Friedman RA; Lee A; Li Y; Goldberg EM; Stratikopoulos EE; Parsons R; Lu C; Efstratiadis A; Philipone EM; Yoon AJ; Su GH
    Mol Cancer Res; 2020 Jun; 18(6):822-834. PubMed ID: 32152233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.
    McBride SM; Rothenberg SM; Faquin WC; Chan AW; Clark JR; Ellisen LW; Wirth LJ
    Head Neck; 2014 Aug; 36(8):1181-8. PubMed ID: 23852799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
    Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
    Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
    Jin N; Keam B; Cho J; Lee MJ; Kim HR; Torosyan H; Jura N; Ng PK; Mills GB; Li H; Zeng Y; Barbash Z; Tarcic G; Kang H; Bauman JE; Kim MO; VanLandingham NK; Swaney DL; Krogan NJ; Johnson DE; Grandis JR
    J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC).
    Saba NF; Dinasarapu AR; Magliocca KR; Dwivedi B; Seby S; Qin ZS; Patel M; Griffith CC; Wang X; El-Deiry M; Steuer CE; Kowalski J; Shin DM; Zwick ME; Chen ZG
    PLoS One; 2020; 15(9):e0238497. PubMed ID: 32986729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma.
    Kobayashi K; Yoshimoto S; Matsumoto F; Ando M; Murakami N; Omura G; Fukasawa M; Matsumoto Y; Matsumura S; Akamatsu M; Hiraoka N; Eigitsu R; Mori T
    Ann Surg Oncol; 2019 Jul; 26(7):2294-2303. PubMed ID: 30900104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Chen X; Cao Y; Sedhom W; Lu L; Liu Y; Wang H; Oka M; Bornstein S; Said S; Song J; Lu SL
    Mol Oncol; 2020 Jan; 14(1):139-158. PubMed ID: 31600013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
    Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
    JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Analytical Validation of a Reverse Transcription Droplet Digital PCR (RT-ddPCR) Assay for PD-L1 Transcripts in Circulating Tumor Cells.
    Strati A; Zavridou M; Economopoulou P; Gkolfinopoulos S; Psyrri A; Lianidou E
    Clin Chem; 2021 Mar; 67(4):642-652. PubMed ID: 33421061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
    Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
    Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
    Theurer JA; Stecho W; Yoo J; Kwan K; Wehrli B; Harry V; Black M; Pinto N; Winquist E; Palma D; Richter S; Barrett JW; Danielle MacNeil S; Fung K; Howlett CJ; Nichols AC
    Pathol Oncol Res; 2016 Jan; 22(1):35-40. PubMed ID: 26271341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models.
    Facompre ND; Rajagopalan P; Sahu V; Pearson AT; Montone KT; James CD; Gleber-Netto FO; Weinstein GS; Jalaly J; Lin A; Rustgi AK; Nakagawa H; Califano JA; Pickering CR; White EA; Windle BE; Morgan IM; Cohen RB; Gimotty PA; Basu D
    Int J Cancer; 2020 Dec; 147(11):3236-3249. PubMed ID: 32478869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas.
    Yarbrough WG; Whigham A; Brown B; Roach M; Slebos R
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S98-101. PubMed ID: 17848307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.